利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

9 条记录 (耗时 0.02 秒)

    ANTIGEN-AND-DRUG VEHICLE COMPRISING SYNTHETIC PEPTIDE, AND MUCOSAL VACCINE USING THE SAME
    1.
    发明公开
    ANTIGEN-AND-DRUG VEHICLE COMPRISING SYNTHETIC PEPTIDE, AND MUCOSAL VACCINE USING THE SAME 有权
    抗原和药物车辆，合成肽，并使用该疫苗SANTANDER粘膜

    公开(公告)号：EP2281574A1

    公开(公告)日：2011-02-09

    申请号：EP09728744.5

    申请日：2009-03-30

    申请人： The University of Tokushima

    发明人： KIDO, Hiroshi ,  TAKEI, Tsunetomo ,  MIZUNO, Dai

    IPC分类号： A61K39/39 ,  A61K39/12 ,  A61P31/00 ,  A61P31/16 ,  A61P37/08 ,  A61P43/00 ,  C07K7/08 ,  C07K14/00

    CPC分类号： A61K39/145 ,  A61K39/12 ,  A61K39/385 ,  A61K2039/541 ,  A61K2039/6018 ,  A61K2039/6031 ,  C07K7/08 ,  C07K14/001 ,  C12N2760/16134

    摘要： Disclosed are an antigen-and-drug (AD) vehicle and a mucosal vaccine utilizing a novel synthetic peptide.
    The antigen-and-drug (AD) vehicle capable of inducing the production of secretory IgA antibodies, which is a complex of a synthetic peptide having the following amino acid sequence: PVHLKRLm (m is 11 to 15 or 16 to 20, e.g., peptide of SEQ. ID. NO: 1) or KnLm (n is 4 to 8 and m is 11 to 20, e.g., peptide of (SEQ. ID. NO: 2 or 3), and a lipid(s). The mucosal vaccines is obtainable by allowing a mucosal-immunity-IgA-inducing amount of an antigen to coexist with, contact, be captured by, or be adsorbed onto the AD vehicle.

    摘要翻译： 本发明公开了在抗原和药物（AD）赋形剂和粘膜疫苗利用一个新的合成肽。 的抗原和药物（AD）载体能够诱导产生分泌型IgA抗体的，所有这些是具有以下氨基酸序列的合成肽的复合物：PVHLKRLm（m是11至15或16至20，例如，肽 （n为4〜8，m为11至20，例如，（SEQ ID NO：2或肽3）：NO SEQ ID 1的）或KnLm，和脂质（一个或多个）所述的粘膜疫苗。 是通过使抗原的粘膜免疫-IgA的诱导量的，接触共存，由被捕获，或放在AD车辆被吸附而得到的。

    DETERMINATION METHOD FOR ALLERGIC DISEASE
    2.
    发明公开
    DETERMINATION METHOD FOR ALLERGIC DISEASE 有权
    BESTIMMUNGSVERFAHRENFÜREINE ALLERGISCHE ERKRANKUNG

    公开(公告)号：EP2136211A1

    公开(公告)日：2009-12-23

    申请号：EP08710396.6

    申请日：2008-02-15

    申请人： The University of Tokushima ,  Oriental Yeast Co., Ltd.

    发明人： KIDO, Hiroshi ,  SUZUKI, Koichi

    IPC分类号： G01N33/53 ,  G01N21/78 ,  G01N33/531 ,  G01N33/543

    CPC分类号： G01N33/6854 ,  G01N33/54373

    摘要： It is to provide a method for determining allergic diseases with a high sensitivity and accuracy which enables multilateral and global analysis with a minute amount of sample, even using body fluid other than blood such as saliva, nasal discharge and tears as a sample, particularly by suppressing nonspecific reaction as much as possible. A chemically modified diamond/DLC (Diamond-like Carbon) chip is activated with a reacting reagent, a coupling reaction with a peptide comprising allergen or allergen epitope is conducted, and a sample such as saliva, tears, and nasal discharge which has undergone pressure filtration with a low protein-adsorbing filter, is contacted with an allergen determination chip to which washing and blocking operations have been performed on unreacted active groups, and an allergen recognizing antibody in the sample captured by the allergen determination chip is detected by immunoassay using a labeled secondary antibody, wherein a glycine-containing solution is used for a washing solution and/or blocking solution used in the washing and blocking operations, is used.

    摘要翻译： 它是提供一种以高灵敏度和精确度确定过敏性疾病的方法，其能够使用少量样品进行多边和全球分析，甚至使用血液以外的体液（如唾液，鼻腔排泄物和泪液）作为样品，特别是通过 尽可能地抑制非特异性反应。 用反应试剂激活化学改性的金刚石/ DLC（类金刚石碳）芯片，进行与包含变应原或变应原表位的肽的偶联反应，以及经历压力的样品例如唾液，泪液和鼻放电 与低蛋白质吸附过滤器的过滤与已对未反应的活性基团进行洗涤和封闭操作的变应原测定芯片接触，并且通过免疫测定法检测由变应原测定芯片捕获的样品中的变应原识别抗体，使用 使用其中含有甘氨酸的溶液用于洗涤和阻塞操作中使用的洗涤溶液和/或封闭溶液。

    METHOD FOR TESTING THE SEVERITY OF AN ILLNESS
    6.
    发明公开
    METHOD FOR TESTING THE SEVERITY OF AN ILLNESS 有权
    VORRICHTUNG ZUM TESTEN DER SCHWERE EINER KRANKHEIT

    公开(公告)号：EP2579037A1

    公开(公告)日：2013-04-10

    申请号：EP11789426.1

    申请日：2011-05-27

    申请人： The University of Tokushima

    发明人： KIDO, Hiroshi ,  NISHIMURA, Masaji ,  CHIDA, Junji

    IPC分类号： G01N33/50 ,  C12Q1/68 ,  G01N33/48

    CPC分类号： G01N33/50 ,  G01N33/5735 ,  G01N2800/00

    摘要： An object of the present invention is directed to a method for assaying the severity of an illness in real time and is to provide a testing method capable of assessing the severity of an illness in more detail than the conventional APACHE II and SOFA scores. The established method can accurately measure an ATP level in a sample, thereby accurately and quickly deducing the "state of intracellular energy required for living organisms" from the ATP level, and by extension, determining the severity of an illness. The present invention further provides a novel biomarker ATP-lactate energy risk score (A-LES) value that is capable of determining the severity of an illness by the reevaluation, with the ATP concentration as an index (specifically, on the basis of a lactic acid level (mM)/ATP concentration (mM) ratio), of the level of lactic acid that accumulates in the sample due to the breakdown of in vivo metabolic balance accompanied by the increased severity of the illness. The present invention also provides a novel biomarker ATP-ketone energy risk score (A-KES) value that is capable of determining the severity of an illness by the reevaluation of a ketone body level in the sample with the ATP concentration as an index (specifically, on the basis of a ketone body level (mM)/ATP concentration (mM) ratio).

    摘要翻译： 本发明的目的是提供一种用于实时测定疾病严重程度的方法，并提供能够比常规APACHE II和SOFA得分更详细地评估疾病的严重程度的测试方法。 所建立的方法可以准确测量样品中的ATP水平，从而准确，快速地从ATP水平推导出“活生物体所需的细胞内能量的状态”，并通过扩展来确定疾病的严重程度。 本发明还提供了一种新的生物标志物ATP-乳酸能量风险评分（A-LES）值，其能够通过重新评估来确定疾病的严重程度，其中ATP浓度作为指标（具体地，基于乳酸 酸浓度（mM）/ ATP浓度（mM）比），由于体内代谢平衡的破坏伴随着疾病的严重程度而累积在样品中的乳酸水平。 本发明还提供了一种新的生物标志物ATP-酮能量风险评分（A-KES）值，其能够通过以ATP浓度作为指标重新评估样品中的酮体水平来确定疾病的严重程度 ，基于酮体水平（mM）/ ATP浓度（mM）比）。

    PROPHYLACTIC/THERAPEUTIC AGENT FOR INFLUENZA VIRUS INFECTION
    9.
    发明公开
    PROPHYLACTIC/THERAPEUTIC AGENT FOR INFLUENZA VIRUS INFECTION 有权
    PROPHYLAKTISCHER ODER THERAPEUTISCHER WIRKSTOFF GEGEN GRIPPEVIRUSINFEKTION

    公开(公告)号：EP2875813A1

    公开(公告)日：2015-05-27

    申请号：EP13819512.8

    申请日：2013-06-03

    申请人： SBI Pharmaceuticals Co., Ltd. ,  The University of Tokushima

    发明人： TANAKA, Tohru ,  NAKAJIMA, Motowo ,  TAKAHASHI, Kiwamu ,  ISHII, Takuya ,  KIDO, Hiroshi ,  CHIDA, Junji ,  YAMANE, Kazuhiko

    IPC分类号： A61K31/197 ,  A61K33/26 ,  A61P3/00 ,  A61P31/16 ,  A61P43/00

    CPC分类号： A61K31/197 ,  A61K31/194 ,  A61K33/26 ,  A61K45/06 ,  A61K2300/00

    摘要： Provided is a prophylactic/therapeutic agent for influenza viral infection that is effective not only before and at an early stage of infection with influenza virus but also at an intermediate or late stage of the infection and is highly safe for human bodies. A prophylactic/therapeutic drug for influenza viral infection comprising, as active ingredients, 5-aminolevulinic acid (5-ALA), a derivative thereof or a salt of the 5-ALA or the derivative, and an iron compound is prepared. This prophylactic/therapeutic agent can be used for ameliorating (preventing) depression in food consumption, water consumption and body weight, for ameliorating (decreasing) increase in ketone body levels in blood that may otherwise cause ketosis, for ameliorating (preventing) depression in ATP levels in blood, or for ameliorating (increasing) a survival rate and depression in a body surface temperature.

    摘要翻译： 提供了一种流感病毒感染的预防/治疗剂，其不仅在感染流感病毒之前和早期阶段都有效，而且在感染的中期或晚期也是有效的，并且对人体是高度安全的。 制备用于流感病毒感染的预防/治疗药物，其包含作为活性成分的5-氨基乙酰丙酸（5-ALA），其衍生物或5-ALA或其衍生物的盐和铁化合物。 该预防/治疗剂可用于改善（预防）食物消耗，饮水和体重中的抑制，以改善（减少）可能引起酮症的血液中酮体水平的升高（降低），以改善（预防）ATP抑制 血液中的水平，或改善（增加）体表温度的存活率和抑郁症。